Characterization of carbapenem-resistant and XDR Pseudomonas aeruginosa in Canada: results of the CANWARD 2007–16 study

Epidemiology and risk factors of extensively drug-resistant Pseudomonas aeruginosa infections

(2018) Nattawan Palavutitotai et al.   PLoS One

In vitro activity of ceftolozane/tazobactam versus antimicrobial non-susceptible Pseudomonas aeruginosa clinical isolates including MDR and XDR isolates obtained from across Canada as part of the CANWARD study, 2008–16

(2017) Andrew Walkty et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

VIM-1, VIM-2, and GES-5 Carbapenemases Among Pseudomonas aeruginosa Isolates at a Tertiary Hospital in Istanbul, Turkey

(2017) Gülşah Malkoçoğlu et al.   Microbial Drug Resistance

Successful control of an outbreak of GES-5 extended-spectrum β-lactamase-producing Pseudomonas aeruginosa in a long-term care facility in Japan

(2016) A. Kanayama et al.   JOURNAL OF HOSPITAL INFECTION

PHYLOViZ Online: web-based tool for visualization, phylogenetic inference, analysis and sharing of minimum spanning trees

(2016) Bruno Ribeiro-Gonçalves et al.   NUCLEIC ACIDS RESEARCH

The increasing threat of Pseudomonas aeruginosa high-risk clones

(2015) Antonio Oliver et al.   DRUG RESISTANCE UPDATES

Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009-11 in 14 European and Mediterranean countries

(2014) M. Castanheira et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Nosocomial infections with metallo-beta-lactamase-producing Pseudomonas aeruginosa: molecular epidemiology, risk factors, clinical features and outcomes

(2014) A. Lucena et al.   JOURNAL OF HOSPITAL INFECTION

Responses of Pseudomonas aeruginosa to antimicrobials

(2014) Yuji Morita et al.   Frontiers in Microbiology

Biological Markers of Pseudomonas aeruginosa Epidemic High-Risk Clones

(2013) Xavier Mulet et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007-11 study

(2013) G. G. Zhanel et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Genetic Markers of Widespread Extensively Drug-Resistant Pseudomonas aeruginosa High-Risk Clones

(2012) Gabriel Cabot et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

OprD mutations and inactivation, expression of efflux pumps and AmpC, and metallo-β-lactamases in carbapenem-resistant Pseudomonas aeruginosa isolates from South Korea

(2012) Ji-Young Lee et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Carbapenem-resistant Gram-negative bacilli in Canada 2009-10: results from the Canadian Nosocomial Infection Surveillance Program (CNISP)

(2012) L. F. Mataseje et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Rapid Detection of Carbapenemase-Producing Pseudomonas spp.

(2012) L. Dortet et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance

(2011) A.-P. Magiorakos et al.   CLINICAL MICROBIOLOGY AND INFECTION

Status report on carbapenemases: challenges and prospects

(2011) Gopi Patel et al.   Expert Review of Anti-Infective Therapy

Plasmid comparison and molecular analysis of Klebsiella pneumoniae harbouring blaKPC from New York City and Toronto

(2011) L. F. Mataseje et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Pseudomonas Aeruginosa: Resistance to the Max

(2011) Keith Poole   Frontiers in Microbiology

Emerging carbapenemases: a global perspective

(2010) Timothy R. Walsh   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Molecular Epidemiology and Mechanisms of Carbapenem Resistance in Pseudomonas aeruginosa

(2009) J.-M. Rodriguez-Martinez et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY